NEW YORK (GenomeWeb) – Illumina is suing Swiss non-invasive prenatal testing firm Genoma for patent infringement.

On behalf of its fully-owned, NIPT-focused subsidiary Verinata Health, Illumina has filed suit against Genoma in Switzerland's Federal Patent Court. In a statement, Illumina said it is seeking all available remedies including damages and injunctive relief.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.